Abstract:Purpose: The contribution of glial cells, mainly astrocytes and microglia, to the pathophysiology of epilepsy is increasingly appreciated. Glia play a pivotal role in the initiation and maintenance of the central nervous system (CNS) immune response and neuronal metabolic and trophic supply. Recent clinical and experimental evidence suggests a direct relationship between epileptic activity and CNS inflammation, which is characterized by accumulation, activation, and proliferation of microglia and astrocytes. Concomitant glia-mediated mechanisms of action of several antiepileptic drugs (AEDs) have been proposed. However, their direct effects on glial cells have been rarely investigated. We aimed to investigate the effect of commonly used AEDs on glial viability, the gap junctional network, the microglial activation, and cytokine expression in an in vitro astroglia/microglia co-culture model. Methods: Primary astrocytic cultures were prepared from brains of postnatal (P0-P2) Wistar rats and co-cultured with a physiologic amount of 5%, as well as 30% microglia in order to mimic inflammatory conditions. Co-cultures were treated with valproic acid (VPA), carbamazepine (CBZ), phenytoin (PHE), and gabapentin (GBT). Viability and proliferation were measured using the tetrazolium (MTT) assay. The microglial activation state was determined by immunocytochemical labeling. The astroglial connexin 43 (Cx43) expression was measured by Western blot analysis. The transforming growth factor-β1 (TGF-β1) and tumor necrosis factor-α (TNF-α) cytokine levels were measured by the quantitative sandwich enzyme immunosorbent assay (ELISA). Key findings: Astrocytes, co-cultured with 5% microglia (M5 co-cultures), showed a dose-dependent, significant reduction in glial viability after incubation with PHE and CBZ. Furthermore, VPA led to highly significant microglial activation at all doses examined. The antiinflammatory cytokine TGF-β1 release was induced by high doses of GBT and PHE. Astrocytes co-cultured with 30% microglia (M30 co-cultures) revealed a dose-dependent significant reduction in glial viability after incubation with PHE, accompanied by increased TGF-β1 and TNF-α levels. However, CBZ significantly reduced the amount of activated microglial cells and increased the total number of inactivated microglia. Finally, CBZ resulted in reduced viability at all doses examined. Significance: CNS inflammation is characterized by a disturbance of glial cell functions. Strong microglial activation, a typical hallmark of inflammation, was induced by VPA in M5 and continued in M30 co-cultures. With regard to the direct relation between CNS inflammation and seizures, VPA seems to be unsuitable for reducing inflammatory conditions. The reverse effect was achieved after CBZ. We noticed significant microglial inactivation, after incubation of the M30 co-cultures. In conclusion, we suggest that AEDs with antiinflammatory glial features are beneficial for seizures caused by persistent brain inflammation.

Targeting microglial GLP1R in epilepsy: A novel approach to modulate neuroinflammation and neuronal apoptosis

Microglia PKM2 Mediates Neuroinflammation and Neuron Loss in Mice Epilepsy through the Astrocyte C3-Neuron C3R Signaling Pathway

Activation of Glucagon-Like Peptide-1 Receptor in Microglia Attenuates Neuroinflammation-Induced Glial Scarring Via Rescuing Arf and Rho GAP Adapter Protein 3 Expressions after Nerve Injury.

Glia and epilepsy: experimental investigation of antiepileptic drugs in an astroglia/microglia co-culture model of inflammation

Microglia in epilepsy

Altered Glutamate Metabolism Contributes to Antiepileptogenic Effects in the Progression from Focal Seizure to Generalized Seizure by Low-Frequency Stimulation in the Ventral Hippocampus

Blockade of Kv1.3 Potassium Channel Inhibits Microglia-Mediated Neuroinflammation in Epilepsy

Neuroinflammation catching nanobubbles for microglia-neuron unit modulation against epilepsy

The GR-ANXA1 pathway is a pathological player and a candidate target in epilepsy

Microglial depletion aggravates the severity of acute and chronic seizures in mice

Conditional Knockout of ASK1 in Microglia/macrophages Attenuates Epileptic Seizures and Long-Term Neurobehavioural Comorbidities by Modulating the Inflammatory Responses of Microglia/macrophages

Unveiling the shield: Troglitazone's impact on epilepsy-induced nerve injury through ferroptosis inhibition

Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4) Mitigates Seizures

Glycoprotein non-metastatic melanoma protein B (GPNMB) protects against neuroinflammation and neuronal loss in pilocarpine-induced epilepsy via the regulation of microglial polarization

EGR1-Driven METTL3 Activation Curtails VIM-Mediated Neuron Injury in Epilepsy

Microglia Mitigate Neuronal Activation in a Zebrafish Model of Dravet Syndrome

GKLF, a transcriptional activator of Txnip , drives microglia activation in kainic acid-induced murine models of epileptic seizures

Activated astrocytes attenuate neocortical seizures in rodent models through driving Na+-K+-ATPase

Ablation of CCL17‐positive hippocampal neurons induces inflammation‐dependent epilepsy

Blocking ERK-DAPK1 Axis Attenuates Glutamate Excitotoxicity in Epilepsy

Regulation of astrocyte glutamate transporter-1 (GLT1) and aquaporin-4 (AQP4) expression in a model of epilepsy